CoChat
Sign Up
Cited by 297Pregnancy and Medication ImpactMaternal Mental Health During Pregnancy and PostpartumAutism Spectrum Disorder Research

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children

Open access
Boukhris, Takoua, Sheehy, Odile, Mottron, Laurent, Bérard, Anick·2016·JAMA Pediatrics
DOI 10.1001/jamapediatrics.2015.3356
Open this paper in CoChat — free accountOpen PDF

Abstract

IMPORTANCE: The association between the use of antidepressants during gestation and the risk of autism spectrum disorder (ASD) in children is still controversial. The etiology of ASD remains unclear, although studies have implicated genetic predispositions, environmental risk factors, and maternal depression. OBJECTIVE: To examine the risk of ASD in children associated with antidepressant use during pregnancy according to trimester of exposure and taking into account maternal depression. DESIGN, SETTING, AND PARTICIPANTS: We conducted a register-based study of an ongoing population-based cohort, the Québec Pregnancy/Children Cohort, which includes data on all pregnancies and children in Québec from January 1, 1998, to December 31, 2009. A total of 145,456 singleton full-term infants born alive and whose mothers were covered by the Régie de l'assurance maladie du Québec drug plan for at least 12 months before and during pregnancy were included. Data analysis was conducted from October 1, 2014, to June 30, 2015. EXPOSURES: Antidepressant exposure during pregnancy was defined according to trimester and specific antidepressant classes. MAIN OUTCOMES AND MEASURES: Children with ASD were defined as those with at least 1 diagnosis of ASD between date of birth and last date of follow-up. Cox proportional hazards regression models were used to estimate crude and adjusted hazard ratios with 95% CIs. RESULTS: During 904,035.50 person-years of follow-up, 1054 children (0.7%) were diagnosed with ASD; boys with ASD outnumbered girls by a ratio of about 4:1. The mean (SD) age of children at the end of follow-up was 6.24 (3.19) years. Adjusting for potential confounders, use of antidepressants during the second and/or third trimester was associated with the risk of ASD (31 exposed infants; adjusted hazard ratio, 1.87; 95% CI, 1.15-3.04). Use of selective serotonin reuptake inhibitors during the second and/or third trimester was significantly associated with an increased risk of ASD (22 exposed infants; adjusted hazard ratio, 2.17; 95% CI, 1.20-3.93). The risk was persistent even after taking into account maternal history of depression (29 exposed infants; adjusted hazard ratio, 1.75; 95% CI, 1.03-2.97). CONCLUSIONS AND RELEVANCE: Use of antidepressants, specifically selective serotonin reuptake inhibitors, during the second and/or third trimester increases the risk of ASD in children, even after considering maternal depression. Further research is needed to specifically assess the risk of ASD associated with antidepressant types and dosages during pregnancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamapediatrics.2015.3356

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. De Jong van den Berg LT, Feenstra N, Sorensen HT, Cornel MC; Europen Medicine and Pregnancy Group. Improvement of drug exposure data in a registration of congenital anomalies: pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy: EuroMAP Group. Teratology. 1999;60(1):33-36.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Boukhris, T., Sheehy, O., Mottron, L., & Bérard, A.
Affiliations
  • Centre Hospitalier Universitaire Sainte-Justine (CA)
  • Hôpital Rivière-des-Prairies (CA)
Corresponding author
Bérard, Anick
ORCID
Venue
JAMA Pediatrics
Publisher
American Medical Association (AMA)
Published
2016-02-01
Volume
170
Issue
2
Pages
117
ISSN
  • 1072-4710 (ISSN-L)
  • 2168-6203
DOI
10.1001/jamapediatrics.2015.3356
OpenAlex
W2217811624
Cited by
297
References
47
Citations by year
2026: 7 · 2025: 12 · 2024: 13 · 2023: 16 · 2022: 20 · 2021: 18 · 2020: 43 · 2019: 30 · 2018: 43 · 2017: 37 · 2016: 57
FWCI
48.94
Type
journal article
Language
en
Open access
Locations
  • Archives of Pediatrics and Adolescent Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
Keywords
antidepressant use during pregnancy, autism spectrum disorder, selective serotonin reuptake inhibitors, maternal depression, prenatal drug exposure, sex differences in autism, drug safety in pregnancy, maternal education, maternal smoking, maternal alcohol use, maternal obesity, maternal diabetes
MeSH terms
Autism Spectrum Disorder, Antidepressive Agents, Child, Child, Preschool, Depression, Female, Humans, Infant, Male, Maternal-Fetal Exchange, Pregnancy, Pregnancy Complications, Pregnancy Trimester, Second, Pregnancy Trimester, Third, Prenatal Exposure Delayed Effects, Quebec, Risk Factors, Proportional Hazards Models, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review